India's Jubilant Pharmova rises as US FDA inspection yields no action
** Shares of Jubilant Pharmova JUBA.NS rise as much as
4.1%, last up 1.2% to 1,030 rupees
** Co says U.S. FDA's inspection of its U.S. contract
manufacturing facility classified as "Voluntary Action
Indicated"
** VAI indicates the agency is not prepared to take or
recommend any administrative or regulatory action, per the U.S.
FDA website
** Stock on track to rise in six out of seven straight
sessions if trend holds
** JUBA up 89% YTD
(Reporting by Varun Vyas in Bengaluru)
((varunvyas.hebbalalu@thomsonreuters.com))
Recent news on Jubilant Pharmova
See all newsBrief: Jubilant Pharmova Sept-Quarter Consol Net Profit 312 Million Rupees
Brief: Jubilant Pharmova Says Jubilant Therapeutics Announces Oral Presentation Of Preliminary Phase 1 Clinical Data For JBI-802
India New Issue-Jubilant Pharmova to issue 3-year bonds, bankers say
India's Jubilant Pharmova eyes $150 mln through rupee debt sale, bankers say
Brief: Jubilant Pharmova To Consider Raising Of Funds Through Issuance Of Non- Convertible Debentures